Latest news with #Valneva
Yahoo
6 days ago
- Business
- Yahoo
Valneva to Participate at U.S. and European Investor Conferences in June
Saint-Herblain (France), May 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and hold investor meetings at several upcoming investor conferences in the United States and Europe in June 2025. Key topics for discussion include Valneva's commercial stage vaccines and its differentiated portfolio of vaccine candidates, including VLA15, the world's leading Lyme disease vaccine candidate. VLA15 is partnered with Pfizer and currently being evaluated in a pivotal Phase 3 trial for which the Company expects first data at the end of 2025. Institutional investors who would like to meet 1on1 with management at any of the below conferences are asked to submit a request to their representative at the respective bank. Jefferies Global Healthcare Conference Format Fireside chat and investor meetingsDate/ time June 5, 2025, 11:40am ETWebcast Link. A replay of the webcast will also be available in the 'Investor' section of the Valneva New York Goldman Sachs 46th Annual Global Healthcare Conference: Format Fireside chat and investor meetingsDate/ time June 9, 2025, 1:20pm ET Location Miami, FL Oddo BHF Nextcap Forum: Format Investor meetings onlyDate/ time June 12, 2025Location Virtual BNP Paribas SMID Cap Conference: Format Investor meetings onlyDate/ time June 18, 2025Location Paris, France About Valneva SE We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against the Zika virus and other global public health threats. More information is available at Valneva Investor and Media ContactsLaetitia Bachelot-FontaineVP, Global Communications and European Investor RelationsM +33 (0)6 4516 Joshua Drumm, Global Investor Relations M +001 917 815 Forward-Looking StatementsThis press release contains certain forward-looking statements relating to the business of Valneva, including with respect to use and regulatory review of existing products. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be sustained in the future. In some cases, you can identify forward-looking statements by words such as 'could,' 'should,' 'may,' 'expects,' 'anticipates,' 'believes,' 'intends,' 'estimates,' 'aims,' 'targets,' or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties and delays involved in the development and manufacture of vaccines, unexpected clinical trial results or new adverse events, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, and the ability to obtain or maintain patent or other proprietary intellectual property protection. Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will in fact be realized. Valneva is providing this information as of the date of this press release and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Attachment 2025_05_26_VLA_June_2025_Conferences_PR_EN_Final
Reuters
21-05-2025
- Health
- Reuters
US CDC accepts recommendations for chikungunya vaccines
May 6 (Reuters) - The U.S. Centers for Disease Control and Prevention has accepted its advisory panel's recommendations on vaccines for chikungunya, a virus transmitted by mosquitoes. The recommendations were approved on May 13, 2025, and are now the official recommendations of the CDC. The final recommendations will assist physicians in choosing appropriate vaccines for patients and will also guide insurance coverage policies in the U.S. The health agency is also expected to decide on recommendations for vaccines against respiratory syncytial virus (RSV) and meningococcal disease, a bacterial infection. However, details regarding the approval status of the RSV and meningococcal vaccine recommendations are currently not available on the CDC's website. Both Bavarian Nordic ( opens new tab and Valneva ( opens new tab make vaccines for chikungunya.
CBC
19-05-2025
- Health
- CBC
London man among thousands who've rolled up their sleeves to trial Lyme disease vaccine
Social Sharing Working outdoors as a landscaper in the summer, Maxwell Dick is at a higher risk than most people of being bitten by a tick and developing a tick-borne disease. The most prevalent of them, and the most common vector-borne disease in North America, is Lyme disease, which has seen case rates soar over the past decade. Despite that, and the potentially debilitating long-term symptoms that can result, including chronic fatigue, body aches and cognition issues, no preventable vaccine is currently available. "There's a lot of people in my industry who get ticks all the time, and to prevent some Lyme disease would be wonderful," Dick said. With that in mind, the London resident and Fanshawe College horticulture instructor signed up for a clinical study for a new, potential Lyme disease vaccine. The clinical trial for the vaccine, VLA15, developed by Pfizer and Valneva, began in August 2022. Stage 3 trials got underway in late 2023 involving more than 9,000 participants from areas of Canada, Europe, and the U.S. where the disease is endemic. Dick says he signed up after seeing a form at his doctor's encouraging participants. "It literally was like, 'Are you a landscaper? Do you like being outdoors? Do you hike? Do you have pets?' I was like, yes to everything," he said. Half of the participants receive three doses of VLA15, while the other half receive three doses of a placebo, both within the first year, followed by a booster a year later. Dick says he expects to find out what he was given in December or January. "They called me (April 14) because I had gotten my blood taken for the last time a few weeks ago, and they were just checking in … It's funny, they're like, 'we don't want you to get a tick, but if you do, that'd be great,'" he said with a chuckle. Pfizer and Valneva say they expect Stage 3 to finish by years-end, and in July said the vaccine had "shown a favourable safety profile across all dose and age groups" in all trials to date. Should the vaccine go to market, it would be the first in more than 20 years. LYMErix, a vaccine from SmithKline Beecham, now GSK plc, was approved in the late 1990s but pulled by the drugmaker in 2002. In 2018, Sam Telford of the original research team blamed the decision on low sales revenue and a class action lawsuit alleging significant adverse reactions. The suit was settled in 2003, with no financial compensation awarded to claimants. The new vaccine is similar in that it also targets the same surface protein (OspA) of the spirochete bacterium that causes Lyme disease, said Dr. George Chaconas of the University of Calgary. There are some differences. "If you get the vaccine, your body develops antibodies to OspA. When the tick takes a blood meal, along with the blood come your antibodies," which kill the bacteria while they're in the tick, he said. "The mechanism is quite cool." Chaconas's research focuses on Borrelia burgdorferi, the bacterium spread through the bite of an infected tick. A tick needs to be attached for at least 24 hours to transmit the bacteria, Health Canada says. Lyme disease is treated with antibiotics, but some may experience post-treatment Lyme disease syndrome, or PTLDS, which is believed to be an autoimmune response, he said. "You don't want to get PTLDS or even Lyme, for that matter. Taking precautions when you're out where you might encounter ticks is important." Cases of Lyme disease continue to climb in Canada, rising in the last decade from 522 in 2014 to 5,229 in 2024, Health Canada says. Infectious disease experts attribute rising awareness among the public and health officials and the warming environment, which is pushing ticks further north. Most major centres in Ontario are established risk areas. "The tick boundary is not static. If you have shorter winters and winters that aren't as cold, ticks can survive and thrive in more northern latitudes," said Dr. Isaac Bogoch, an infectious disease specialist at Toronto General Hospital. It raises concerns about other tick-borne diseases, such as anaplasmosis, babesiosis, and Powassan virus, which were designated tick-borne diseases of public health significance in Ontario in 2023. Lyme disease gets more attention, "as it should," Bogoch says, "but we shouldn't ignore the other ones." Case figures of the diseases are likely significant undercounts, he said. Many may not recognize signs and symptoms, or seek out medical attention. "They're not hard to diagnose, and they're not hard to treat. This is just an issue of being aware that they're around and identifying them," he said.
New York Post
16-05-2025
- Health
- New York Post
Seniors should avoid this vaccine after deadly complications discovered, FDA says
Older adults are being warned against receiving the chikungunya vaccine before traveling. The Ixchiq vaccination, developed by Valneva to prevent the mosquito-borne chikungunya virus, was approved by the Food and Drug Administration (FDA) in November 2023 as the first of its kind. The approval applies to anyone aged 18 and older who has a risk of being exposed to the virus. But the FDA and the Centers for Disease Control and Prevention (CDC) released a safety notice on May 9 recommending that adults over 60 years old pause use of the vaccine due to fatal complications. 'FDA and CDC will continue the evaluation of post-marketing safety reports for Ixchiq,' the release reads. 'While the safety of Ixchiq for use in individuals 60 years of age and older is being further assessed, FDA and CDC are recommending a pause in use of the vaccine in this age group. FDA and CDC will update the public when the agencies complete their evaluation of this safety issue.' 3 The FDA is advising seniors to avoid getting the chikungunya vaccine before traveling. InsideCreativeHouse – The advisory follows reports of 'serious adverse events,' including neurologic and cardiac events in people who received the vaccine. Two of 17 events resulted in death from severe complications. One death was caused by encephalitis, or inflammation in the brain, the alert stated. 3 The Ixchiq vaccination was developed to prevent the mosquito-borne chikungunya virus. wirakorn – Those who experienced adverse effects of the vaccine were reported to be between the ages of 62 and 89. The FDA warned that Ixchiq, which contains a live, weakened version of chikungunya, may cause symptoms similar to the virus. Typical symptoms of chikungunya include fever, severe joint pain, headache, muscle pain and a rash, according to the CDC. Most people recover within a week, but some may experience 'severe and disabling' joint pain for weeks or months. 3 A patient infected with chikungunya looks out from mosquito netting at the Clinicas Hospital in San Lorenzo, Paraguay, in 2023. AP 'This virus is in a similar category as dengue or Zika and is carried by the same mosquitoes,' Fox News senior medical analyst Dr. Marc Siegel previously told Fox News Digital. At the time of the vaccine's approval, the FDA described chikungunya as an 'emerging global health threat,' with at least five million cases reported over the past 15 years. The FDA plans to conduct an 'updated benefit-risk assessment' for Ixchiq use in those over 60 years of age, according to the notice.
Fox News
13-05-2025
- Health
- Fox News
FDA warns seniors to avoid this vaccine after deadly complications
Older adults are being warned against receiving the chikungunya vaccine before traveling. The Ixchiq vaccination, developed by Valneva to prevent the mosquito-borne chikungunya virus, was approved by the Food and Drug Administration (FDA) in November 2023 as the first of its kind. The approval applies to anyone aged 18 and older who has a risk of being exposed to the virus. But the FDA and the Centers for Disease Control and Prevention (CDC) released a safety notice on May 9 recommending that adults over 60 years old pause use of the vaccine due to fatal complications. "FDA and CDC will continue the evaluation of post-marketing safety reports for Ixchiq," the release reads. "While the safety of Ixchiq for use in individuals 60 years of age and older is being further assessed, FDA and CDC are recommending a pause in use of the vaccine in this age group. FDA and CDC will update the public when the agencies complete their evaluation of this safety issue." The advisory follows reports of "serious adverse events," including neurologic and cardiac events in people who received the vaccine. Two of 17 events resulted in death from severe complications. One death was caused by encephalitis, or inflammation in the brain, the alert stated. Those who experienced adverse effects of the vaccine were reported to be between the ages of 62 and 89. The FDA warned that Ixchiq, which contains a live, weakened version of chikungunya, may cause symptoms similar to the virus. Typical symptoms of chikungunya include fever, severe joint pain, headache, muscle pain and a rash, according to the CDC. Most people recover within a week, but some may experience "severe and disabling" joint pain for weeks or months. "This virus is in a similar category as dengue or Zika and is carried by the same mosquitoes," Fox News senior medical analyst Dr. Marc Siegel previously told Fox News Digital. At the time of the vaccine's approval, the FDA described chikungunya as an "emerging global health threat," with at least five million cases reported over the past 15 years. For more Health articles, visit The FDA plans to conduct an "updated benefit-risk assessment" for Ixchiq use in those over 60 years of age, according to the notice.
